|Videos|April 19, 2019

Reducing Antibiotic Prescriptions for Patients Without Evidence of UTI

Laura Shallcross, PhD, discusses how clinicians have “a low threshold” for initiating antibiotics in the emergency department for patients with symptoms similar to a UTI.

Segment Description: Laura Shallcross, PhD, MBBS, MSc, of University College London, discusses show clinicians have “a low threshold” for initiating antibiotics in the emergency department for patients with symptoms similar to a urinary tract infection (UTI).

Interview transcript (modified slightly for readability):

So, I think it's really difficult and it goes back to this thing about having a low threshold. It's really hard to not give an antibiotic to somebody when they come in because they could be really unwell. But, what we can do, is in the 24 hours or the 48 hours after they've come into hospital, we can look at them again and ‘say does that patient really need an antibiotic?’ Now we've got more information to know what's wrong with them. So, it's about looking again at that prescribing decision.

Something I'm quite excited about is we're starting to develop models using data from the electronic health records, but using data from many more patients, so from tens of thousands of patients, to start saying can we predict which patients need antibiotics and which ones don't. So, we can try and give doctors more information to work out who they can stop antibiotics in.

Learn more about Shallcross’ study on inappropriate prescriptions here.


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.